Results 61 to 70 of about 48,974 (212)

Prognosis-related molecular subtyping in head and neck squamous cell carcinoma patients based on glycolytic/cholesterogenic gene data

Cancer Cell International, 2023
Background Head and neck squamous cell carcinoma (HNSCC) remains an unmet medical challenge. Metabolic reprogramming is a hallmark of diverse cancers, including HNSCC.
Zekun Zhou, Jianfei Tang, Yixuan Lu, Jia Jia, Tiao Luo, Kaixin Su, Xiaohan Dai, Haixia Zhang, Ousheng Liu   +8 more
doaj   +1 more source

HPV and CSC in HNSCC cisplatin resistance

Frontiers in Bioscience, 2015
Cisplatin (DNA intercalator), a standard chemotherapy drug often used to treat head and neck squamous cellular carcinoma (HNSCC) has very low response rates in recurrent disease of HNSCC, this is a major clinical problem today. However, a valuable window to look in to the underlying molecular aspects of a favorable and unfavorable cisplatin response is
Vishnu, Modur, K, Thomas-Robbins, Krishna, Rao   +2 more
openaire   +2 more sources

Long non-coding RNA DUXAP9 promotes the proliferation and metastasis of head and neck squamous cell carcinoma

口腔疾病防治, 2022
Objective To investigate the role of long non-coding RNA double homeobox A pseudogene 9 (DUXAP9) in head and neck squamous cell carcinoma (HNSCC) and to evaluate the expression level, molecular function and mechanism of DUXAP9 in HNSCC cells.
ZHOU Wenkai, WANG Jiaxuan, WANG Yuanfeng, CHEN Meng, TAO Xingru, LIU Zheqi, ZHANG Xu, JI Tong, CAO Wei   +8 more
doaj   +1 more source

Nivolumab Doubles Survival for Patients with HNSCC [PDF]

Cancer Discovery, 2016
Abstract In patients with head and neck squamous cell carcinoma refractory to platinum-based chemotherapy, those treated with nivolumab had a 30% reduction in the risk of death compared with those assigned to receive one of three single-agent chemotherapies, according to a recent phase III trial.
openaire   +2 more sources

Deciphering a Prognostic Signature Based on Soluble Mediators Defines the Immune Landscape and Predicts Prognosis in HNSCC

Frontiers in Bioscience-Landmark
Background: The study on Head and Neck Squamous Cell Carcinoma (HNSCC), a prevalent and aggressive form of head and neck cancer, focuses on the often-overlooked role of soluble mediators.
Hao Chi, Gaoge Peng, Guobin Song, Jinhao Zhang, Xixi Xie, Jinyan Yang, Jiayu Xu, Jieying Zhang, Ke Xu, Qibiao Wu, Guanhu Yang   +10 more
doaj   +1 more source

Novel insight into mutational landscape of head and neck squamous cell carcinoma. [PDF]

PLoS ONE, 2014
Development of head and neck squamous cell carcinoma (HNSCC) is characterized by accumulation of mutations in several oncogenes and tumor suppressor genes.
Daria A Gaykalova, Elizabeth Mambo, Ashish Choudhary, Jeffery Houghton, Kalyan Buddavarapu, Tiffany Sanford, Will Darden, Alex Adai, Andrew Hadd, Gary Latham, Ludmila V Danilova, Justin Bishop, Ryan J Li, William H Westra, Patrick Hennessey, Wayne M Koch, Michael F Ochs, Joseph A Califano, Wenyue Sun   +18 more
doaj   +1 more source

CD73 is associated with poor prognosis in HNSCC

Oncotarget, 2016
CD73 is a cell surface immunosuppressive enzyme involved in tumor progression and metastasis. While patients whose cancer cells express elevated CD73 are typically associated with an unfavorable outcome, the clinical impact of CD73 expression in patients with Head and neck squamous cell carcinoma (HNSCC) remains unclear.
Ren, Zhen-Hu, Lin, Cheng-Zhong, Cao, Wei, Yang, Rong, Lu, Wei, Liu, Zhe-Qi, Chen, Yi-Ming, Yang, Xi, Tian, Zhen, Wang, Li-Zhen, Li, Jiang, Wang, Xu, Chen, Wan-Tao, Ji, Tong, Zhang, Chen-Ping   +14 more
openaire   +3 more sources

Identification of a potential prognostic panel of biomarkers for stratification of head and neck squamous cell carcinoma based on HPV status and TP53 mutational status

Oral Oncology Reports, 2023
Head and Neck Squamous Cell Carcinoma (HNSCC) is a malignant cancer with poor prognosis. Currently, the prognosis of HNSCC is determined by clinical and histopathological criteria. This work focused on identifying a panel of genes that have the potential
Oriana Barros, Rita Ferreira, Vito G. D'Agostino, Francisco Amado, Lucio Santos, Rui Vitorino   +5 more
doaj   +1 more source

Top 15 light HNSCC mutation enriched pathways.

, 2019
Top 15 light HNSCC mutation enriched pathways.
Shannon K. McWeeney (226756), Myles Vigoda (7481147), Nathaniel Evans (7481144), Christina Zheng (151321), Molly Kulesz-Martin (162511), Jeffrey W. Tyner (7481153), Mitzi Boardman (7481129), Samuel Higgins (2149879), Sophia Jeng (7481132), Ashley Anderson (7481138), Gabrielle Choonoo (3325773), Aurora S. Blucher (7481126), James Jacobs (7481135), Benjamin Cordier (7481150), Steven Chamberlin (7481141), Ted Laderas (3348728)   +15 more
core   +1 more source

Analysis of myosin genes in HNSCC and identify MYL1 as a specific poor prognostic biomarker, promotes tumor metastasis and correlates with tumor immune infiltration in HNSCC

, 2023
Head neck squamous cell carcinoma (HNSCC) is one of the most common malignant tumors which ranks the sixth incidence in the world. Although treatments for HNSCC have improved significantly in recent years, its recurrence rate and mortality rate remain ...
Wenming Li, Fen Chang, Dapeng Lei, Dongmin Wei, Long Chen, Ce Li, Qun Wei, Ran Wei, Chenyang Xu, Kainan Wu, Rui Guan, Shengda Cao   +11 more
core   +1 more source